TACC3 Antibody (C-5): sc-271165
- TACC3 Antibody (C-5) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- raised against a peptide mapping near the N-terminus of TACC3 of human origin
- recommended for detection of TACC3 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for TACC3 Antibody (C-5) for WB and IHC(P) applications. These reagents are now offered in bundles with TACC3 Antibody (C-5) (see ordering information below).
QUICK LINKS
TACC3 Antibody (C-5) is a mouse monoclonal IgG2a antibody that detects TACC3 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). TACC3, a member of the transforming acidic coiled-coil (TACC) protein family, plays a crucial role in cell division and genomic stability maintenance, making TACC3 significant in cancer research. TACC3 primarily localizes in the cytoplasm and associates with microtubules and centrosomes, which are essential for proper spindle assembly during mitosis. TACC3′s interaction with these structures is vital for accurate chromosome segregation, and dysregulation can lead to aneuploidy, a hallmark of many cancers. TACC3 has been implicated in cell cycle progression regulation and interacts with other proteins involved in mitotic processes, highlighting TACC3′s importance in cellular proliferation and tumorigenesis. Anti-TACC3 antibody (C-5) serves as an invaluable tool for researchers studying cell division and cancer biology.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TACC3 Antibody (C-5) References:
- Aberrations of TACC1 and TACC3 are associated with ovarian cancer. | Lauffart, B., et al. 2005. BMC Womens Health. 5: 8. PMID: 15918899
- FGFR3-TACC3: A novel gene fusion in cervical cancer. | Carneiro, BA., et al. 2015. Gynecol Oncol Rep. 13: 53-6. PMID: 26425723
- TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis. | Du, Y., et al. 2016. Oncotarget. 7: 41885-41897. PMID: 27248823
- TACC3 transcriptionally upregulates E2F1 to promote cell growth and confer sensitivity to cisplatin in bladder cancer. | Lin, ZR., et al. 2018. Cell Death Dis. 9: 72. PMID: 29358577
- Inhibition of TACC3 by a small molecule inhibitor in breast cancer. | Campo, L. and Breuer, EK. 2018. Biochem Biophys Res Commun. 498: 1085-1092. PMID: 29555478
- TACC3 expression as a prognostic factor in aggressive types of adult T-cell leukemia/lymphoma patients. | Moritsubo, M., et al. 2020. Int J Lab Hematol. 42: 842-848. PMID: 32744749
- HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion. | Li, T., et al. 2022. Mol Ther. 30: 1610-1627. PMID: 35151844
- E2F1 promotes cell cycle progression by stabilizing spindle fiber in colorectal cancer cells. | Fang, Z., et al. 2022. Cell Mol Biol Lett. 27: 90. PMID: 36221072
- Tumor-augmenting Effect of Histone Methyltransferase WHSC1 on Colorectal Cancer Via Epigenetic Upregulation of TACC3 and PI3K/Akt Activation. | Fan, Y., et al. 2022. Arch Med Res. 53: 658-665. PMID: 36336500
- TACC3 is an independent prognostic marker, and knockdown of TACC3 enhances the efficacy of CDK1 inhibitor RO3306 in liver cancer cells. | Guo, E., et al. 2023. J Biochem Mol Toxicol. 37: e23402. PMID: 37341435
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TACC3 Antibody (C-5) | sc-271165 | 200 µg/ml | $322.00 | |||
TACC3 Antibody (C-5): m-IgG Fc BP-HRP Bundle | sc-537578 | 200 µg Ab; 10 µg BP | $361.00 | |||
TACC3 Antibody (C-5): m-IgGκ BP-HRP Bundle | sc-534882 | 200 µg Ab; 40 µg BP | $361.00 | |||
TACC3 (C-5) Neutralizing Peptide | sc-271165 P | 100 µg/0.5 ml | $69.00 |